Login to Your Account

Proposed CBE Rule Could Increase Generic Liability

By Mari Serebrov
Washington Editor

Tuesday, July 9, 2013
The FDA is working on revisions to its labeling regulations that could revoke the free pass the Supreme Court has handed generic drugmakers when it comes to state failure-to-warn claims.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription